Uptake of hepatitis C treatment by injecting drug users (IDUs) remains low and little is known about factors influencing treatment uptake by ethnic minority groups. The influence of notions of “candidacy” on “accomplishing” access to antiviral treatment are explored using data from an ethnographic study. Fieldwork and in-depth interviews were conducted with 72 Indo-Chinese IDUs. Cultural contexts, everyday realities of drug use and marginalization, and disengagement from the health system produced notions of candidacy in participants' local worlds. Among the minority assessed for treatment, adjudications of candidacy were perceived to be influenced by power dynamics. Demonstrating abstinence from drug use was understood to be central to establishing legitimate claims for candidacy, suggesting conflicting provider, patient, and public health perspectives. Further research is needed to identify drivers of institutional notions of candidacy and determine ways to ensure these do not produce discriminatory practices and policies that exclude and disadvantage particular groups.
BackmundM.MeyerK.Von ZielonkaM., & EichenlaubD. (2001). Treatment of hepatitis C infection in injection drug users. Hepatology, 34(1), 188–193.
3.
BelfioriB.CilegiP.ChioderaA.BacosiD.TostiA.BaldelliF. (2009). Peginterferon plus ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Digestive and Liver Disease, 41, 303–307.
4.
BirkheadG.KleinS.CandelasA.O'ConnellD.RothmanJ.FeldmanI. (2007). Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: A comprehensive approach. International Journal of Drug Policy, 18(5), 417–425.
5.
BourdieuP., & WacquantL. (1992). An invitation to reflexive sociology. Cambridge: Cambridge University Press.
6.
BruggmannP.FalcatoL.DoberS.HelblingB.KeiserF.NegroF. (2008). Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rate in adherent patients. Journal of Viral Hepatitis15(10), 747–752.
7.
Commonwealth Department of Health and Ageing. (2010). Third National Hepatitis C Strategy 2010–2013. Canberra: Author.
8.
CooperC., & MillsE. (2006). Therapeutic challenges in hepatitis C-infect-ed injection drug using patients. Harm Reduction Journal, 3, e31.
9.
CouplandH.DayC.LevyM. T., & MaherL. (2009). Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users. Health Promotion Journal of Australia, 20(3), 234–240.
10.
CouplandH.RitchieJ., & MaherL. (2004). Within reach: A participatory needs assessment of young injecting drug users in South Western Sydney. Sydney: School of Public Health and Community Medicine, University of New South Wales.
11.
CournotM.GlibertA.CastelF.DruartF.ImaniK.Lauwers-CancesV. (2004). Management of hepatitis C in active drug users: Experiences of an addiction care hepatology unit. Gastroenterologie Clinique et Biologique, 28, 533–539.
12.
DavisG., & RodrigueJ. (2001). Treatment of chronic hepatitis C in active drug users. New England Journal of Medicine, 345(3), 215–217.
13.
Dixon-WoodsM.CaversD.AgarwalS.AnnandaleE.ArthurA.HarveyJ. (2006). Conducting a critical interpretive synthesis of the literature on access to health care by vulnerable groups. BMC Medical Research Methodology, 6, 35–48.
14.
DoabA.TreloarC., & DoreG. (2005). Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clinical Infectious Diseases, 40(Suppl. 5), 313–320.
15.
DoreG. (2007). Enhancing hepatitis C treatment uptake and outcomes for injection drug users. Hepatology, 45(1), 3–5.
16.
EdlinB.SealK.LorvickJ.KralA.CiccaroneD.MooreL. (2001). Is it justifiable to withhold treatment for hepatitis C from illicit drug users?New England Journal of Medicine, 345(3), 211–214.
17.
FraserS., & MooreD. (2008). Dazzled by unity? order and chaos in public discourse on illicit drug use. Social Science & Medicine, 66(3), 740–752.
18.
FraserS., & TreloarC. (2006). “Spoiled identity” in hepatitis C infection: The binary logic of despair. Critical Public Health, 16(2), 99–110.
19.
GiddingH.ToppL.MiddletonM.RobinsonK.HellardM.McCaughanG. W. (2009). The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations. Journal of Gastroenterology and Hepatology, 24, 1648–1654.
20.
GlaserB. G., & StraussA. (1967). The discovery of grounded theory: Strategies for qualitative research. Chicago: Aldine.
21.
GoffmanE. (1963). Stigma: Notes on the management of spoiled identity. New York: Simon & Schuster.
22.
GrebelyJ.GenowayK.KharaM.DuncanF.ViljoenM.ElliottD. (2007). Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. International Journal of Drug Policy, 18(5), 437–443.
23.
GrebelyJ.GenowayK.RaffaJ.DhadwalG.RajanT.ShowlerG. (2008). Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence, 93(1–2), 141–147.
24.
HainesD.RutherfordD., & ThomasP. (1981). Family and community among Vietnamese refugees. International Migration Review, 15(1), 310–319.
25.
HallinanR.ByrneA., & DoreG. (2007). Harm reduction, hepatitis C and opioid pharmacotherapy: An opportunity for integrated hepatitis C virus-specific harm reduction. Drug and Alcohol Review, 26(4), 437–443.
26.
HellardM.NguyenO.GuyR.JardineD.MijchA., & HiggsP. G. (2006). The prevalence and risk behaviours associated with the transmission of blood-borne viruses among ethnic Vietnamese injecting drug users in Victoria. Australian and New Zealand Journal of Public Health, 30(6), 519–525.
27.
HellardM.Sacks-DavisR., & GoldJ. (2009). Hepatitis C treatment for injection drug users: A review of the available evidence. Clinical Infectious Diseases, 49, 561–573.
28.
HiggsP.JordensJ.MaherL., & DunlopA. (2009). Vietnamese-Australian heroin users' perspectives on the role of the family in treatment, Melbourne Australia. Drugs: Education, Prevention and Policy, 16(5), 409–421.
29.
HoH. T. (2006). Culture, risk and vulnerability to blood-borne viruses among ethnic Vietnamese injecting drug users. Univerity of New South Wales, Sydney.
30.
HoH. T., & MaherL. (2008). Có vay có tra (What goes around comes around): Culture, risk and vulnerability to blood-borne viruses among ethnic Vietnamese injecting drug users. Drug and Alcohol Review, 27(4), 420–428.
31.
HopwoodM., & TreloarC. (2007). The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection. International Journal of Drug Policy, 18, 374–380.
32.
KresinaT.KhalsaJ.CesariH., & FrancisH. (2005). Hepatitis C virus infection and substance abuse: Medical management and developing models of integrated care. Clinical Infectious Diseases, 40(Suppl. 5), 259–262.
33.
Leclerc-MadlalaS. (2009). Cultural scripts for multiple concurrent partnerships in southern Africa: Why HIV prevention needs anthropology. Sexual Health, 6, 103–110.
34.
LesterR. C. (1973). Theravada Buddhism in Southeast Asia. Ann Arbor: University of Michigan Press.
35.
LitwinA.HarrisK.JrNahviS.ZamorP.SolowayI.TenoreP. (2009). Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Journal of Substance Abuse Treatment, 37(1), 32–40.
36.
LutfeyK. (2005). On practices of “good doctoring”: Reconsidering the relationship between provider roles and patient adherence. Sociology of Health and Illness, 27(4), 421–447.
37.
MACASHH. (2006). Hepatitis C virus projections working group: Estimates and projections of the hepatitis C virus epidemic in Australia 2006. Sydney: National Centre in HIV Epidemiology and Clinical Research.
38.
MaherL.DixonD.LynskeyM., & HallW. (1998). Running the risks: Heroin, health and harm in South West Sydney. Sydney: National Drug and Alcohol Research Centre, University of New South Wales.
39.
MaherL., & HoT. (1998). Wall of Silence: Stories of Cabramatta street youth. Sydney: Tin Sheds Gallery.
40.
MaherL.JalaludinB.ChantK.JayasuriyaR.SladdenT.KaldorJ. (2006). Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction, 101, 1499–1508.
41.
MatthewsG.KronborgI., & DoreG. (2005). Treatment for hepatitis C virus infection among current injection drug users in Australia. Clinical Infectious Diseases, 40(Suppl. 5), 325–329.
42.
MaussS.BergerF.GoelzJ.JacobB., & SchmutzG. (2004). A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology, 40, 120–124.
43.
MehtaS.GenbergB.AstemborskiJ.KavaseryR.KirkG.VlahovD. (2008). Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health, 33, 126–133.
44.
MooreD. (2009). “Workers,” “clients” and the struggle over needs: Understanding encounters between service providers and injecting drug users in an Australian city. Social Science & Medicine, 68(6), 1161–1168.
45.
Munoz-PlazaC. E.StraussS.Astone-TwerellJ.JarlaisD. D.GwadzM.HaganH. (2008). Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S.International Journal of Drug Policy, 19(1), 71–78.
46.
NCHECR. (2010). Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.
47.
NovickD., & KreekM. (2008). Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction, 103(6), 905–918.
48.
ReidG.HiggsP.BeyerL., & CroftsN. (2002). Vulnerability among Vietnamese illicit drug users in Australia: Challenges for change. International Journal of Drug Policy, 13(2), 127–136.
49.
SchaferM.HeinzA., & BackmundM. (2004). Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules. Addiction, 99, 1167–1175.
50.
ScheftH., & FontenetteD. (2005). Psychiatric barriers to readiness for treatment for hepatitis C virus infection among injection drug users: Clinical experience of an addiction psychiatrist in the HIV-HCV coin-fection clinic of a public health hospital. Clinical Infectious Diseases, 40(Suppl. 5), 292–296.
51.
StooveM.GiffordS., & DoreG. (2005). The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug and Alcohol Dependence, 77, 81–86.
52.
StrathdeeS.LatkaM.CampbellJ.O'DriscollP.GolubE.KapadiaF. (2005). Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clinical Infectious Diseases, 40(Suppl. 5), 304–312.
53.
SylvestreD. (2005). Treating hepatitis C virus infection in active substance users. Clinical Infectious Diseases, 40(Suppl. 5), 321–324.
54.
SylvestreD., & ZwebenJ. (2007). Integrating HCV services for drug users: A model to improve engagement and outcomes. International Journal of Drug Policy, 18(5), 406–410.
55.
TreloarC.NewlandJ.RanceJ., & HopwoodM. (2010). Uptake and delivery of hepatitis C treatment in opiate substitution treatment: Perceptions of clients and health professionals. doi:10.1111/j.1365-2893.2009.01250.x. Journal of Viral Hepatitis, 17(2), 839–844.
56.
WalleyA.WhiteM.KushelM.SongY., & TulskyJ. (2005). Knowledge of and interest in hepatitis C treatment at a methadone clinic. Journal of Substance Abuse Treatment, 28(2), 181–187.
